What is the appropriate dose of colistin for a term male infant with intra‑uterine growth restriction, birth weight 1.6 kg, who is 7 days old?

Colistin Dosing for Term IUGR Neonate

For this 7-day-old term infant with IUGR and birth weight of 1.6 kg, administer colistin at 2.5-5 mg CBA/kg/day divided into 2-4 doses (approximately 4-8 mg CBA total daily dose, divided into 2-4 doses). 111

Dosing Algorithm

Based on the most recent guideline recommendations 111:

• Standard pediatric dose: 2.5-5 mg colistin base activity (CBA)/kg/day IV in 2 or 4 divided doses
• For this 1.6 kg infant:
  • Lower range: 4 mg CBA/day (1 mg CBA every 6 hours OR 2 mg CBA every 12 hours)
  • Upper range: 8 mg CBA/day (2 mg CBA every 6 hours OR 4 mg CBA every 12 hours)
• Maximum dose: 100 mg CBA/dose

Dose Selection Considerations

Start at the higher end (5 mg CBA/kg/day) if:

• MIC of the pathogen is ≥1 mg/L
• Severe infection (pneumonia, bloodstream infection, meningitis)
• Good renal function for age 1111

Start at the lower end (2.5 mg CBA/kg/day) if:

• Mild-moderate infection
• Concern for renal function
• Prophylactic use

Critical Implementation Points

Dosing Conversion

The dose unit requires careful attention 2:

• 1 million U = 80 mg mass CMS = 33 mg CBA
• If using colistimethate sodium (CMS), convert appropriately

Renal Function Monitoring

This is non-negotiable 111111:

• Monitor serum creatinine before, during, and after treatment
• Check electrolytes (especially magnesium and potassium) closely - these infants are at high risk for hypomagnesemia and hypokalemia 34
• In VLBW infants, magnesium levels drop significantly during colistin therapy (1.30 vs 1.70 mg/dL, p<0.001) 3
• Acute kidney injury occurs in approximately 19-24% of preterm infants 45

Combination Therapy

Strongly consider combination therapy over monotherapy 2:

• Polymyxin combination therapy is recommended as preferential choice for CRGNB infections
• Combine with carbapenem if meropenem MIC allows, or other susceptible agents
• Even if second agent lacks in vitro activity, combination may improve outcomes 111111

Special Considerations for This Patient

IUGR and Low Birth Weight Context

This term infant with IUGR (1.6 kg at term) requires special attention:

• Use actual body weight for dosing calculation (1.6 kg), not ideal body weight
• VLBW infants (<1500g) show similar efficacy to non-VLBW infants (89.3% vs 86.8% microbiological clearance) 3
• However, they have significantly higher risk of electrolyte disturbances 34

Evidence Quality Note

The optimal pediatric dosing remains uncertain 1111. Recent pharmacokinetic studies suggest FDA/EMA recommendations (equivalent to 2.5-5 mg CBA/kg/day) may be inadequate when:

• Pathogen MIC ≥1 mg/L
• Augmented renal clearance present
• Good renal function for age 1111

However, a 2021 prospective PPK study 6 demonstrated that 5 mg CBA/kg/day resulted in only 18.2-63.0% probability of achieving target Css,avg of 2 mg/L, suggesting higher doses (7.5 mg CBA/kg/day) may be needed for optimal outcomes in children with low serum creatinine.

Duration and Monitoring

• Typical duration: 9-14 days based on clinical response 345
• Monitor for nephrotoxicity every 2-3 days minimum
• Replace electrolytes proactively, especially magnesium and potassium
• All observed renal and electrolyte abnormalities were reversible in surviving patients 45

Common Pitfall

Do not underdose: 60.3% of pediatric patients receive doses below FDA/EMA recommendations 7, which may contribute to treatment failure. Given the severity of multidrug-resistant infections, err toward the higher end of the dosing range (5 mg CBA/kg/day) unless contraindicated.